Clinical trials: Neurofibromatoses

Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1)

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

• Active, not recruiting
• Age: 2 years and older
• Phase 2
• Pill or oral medicine
• Results posted

This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901).

Trial name

ReNeu (NCT03962543)

Testing

Mirdametinib (PD-0325901) oral capsule or dispersible tablet

Where

43 sites in United States

Volunteers

114 people

Sponsor

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany